"instanceType","name","uuid:ID","description","label","rationale","id"
"StudyDesign","Study Design 1","440eca94-ea29-4de4-b827-6f2e1ecf9128","The main design for the study","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1"
